Novo Nordisk pays $800m for start-up’s diabetes tech platform

20-08-2018

Novo Nordisk pays $800m for start-up’s diabetes tech platform

blackjack3d / iStockphoto.com

Novo Nordisk has bought a University of Bristol spin-out company for $800 million, in a deal which could transform the way diabetes is treated.


Novo Nordisk, Ziylo, University of Bristol, acquisition, diabetes, research, blood sugar, technology platform, metabolic control

LSIPR